Publications by authors named "A Coosemans"
Article Synopsis
- Circulating cell-free DNA (cfDNA) is being studied as a noninvasive marker for cancer detection, and understanding its origins could enhance cancer diagnosis and treatment management.* -
- The researchers created MetDecode, a deconvolution algorithm that identifies cancer tissue origins using DNA methylation patterns, and built a reference atlas from existing data for various cancers.* -
- MetDecode showed high accuracy, correctly identifying tissue origins in 84.2% of plasma cfDNA samples from cancer patients, and can be accessed online for further use.*
Purpose: Patients with high-grade serous ovarian carcinoma (HGSOC) are virtually insensitive to immune checkpoint inhibitors (ICI) employed as standalone therapeutics, at least in part reflecting microenvironmental immunosuppression. Thus, conventional chemotherapeutics and targeted anticancer agents that not only mediate cytotoxic effects but also promote the recruitment of immune effector cells to the HGSOC microenvironment stand out as promising combinatorial partners for ICIs in this oncological indication.
Experimental Design: We harnessed a variety of transcriptomic, spatial, and functional assays to characterize the differential impact of neoadjuvant paclitaxel-carboplatin on the immunological configuration of paired primary and metastatic HGSOC biopsies as compared to neoadjuvant chemotherapy (NACT)-naïve HGSOC samples from five independent patient cohorts.
Background: Ovarian cancer is the leading cause of mortality among gynecological malignancies. Carboplatin and poly (ADP-ribose) polymerase inhibitors (PARPi) are often implemented in the treatment of ovarian cancer. Homologous recombination deficient (HRD) tumors demonstrate increased sensitivity to these treatments; however, many ovarian cancer patients are homologous recombination proficient (HRP).
View Article and Find Full Text PDF